Dr. Elias Discusses the Future of Androgen Receptors in Breast Cancer
Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer.
Currently, there is a maturing, randomized phase II study of exemestane, plus or minus, enzalutamide in AR-positive breast cancer, says Elias.
Data have been collected in triple-negative breast cancer with enzalutamide, and Elias says it is fairly compelling. He adds that there is potential action on more aggressive, triple-negative breast cancer, and Elias believes combinations will be particularly significant. Examples include combinations with anti-estrogen therapy and everolimus, anti-estrogen therapy and palbociclib, CDK4/6 inhibitors with enzalutamide, etc.
Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses the future of androgen receptors in breast cancer.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
